Neurocrine Biosciences Inc (NBIX)

48.98
0.46 0.93
NASDAQ : Health Care
Prev Close 49.44
Open 49.58
Day Low/High 47.80 / 50.30
52 Wk Low/High 31.25 / 58.46
Volume 1.07M
Avg Volume 1.02M
Exchange NASDAQ
Shares Outstanding 86.75M
Market Cap 4.47B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2016 Results

Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2016 Results

Conference Call and Webcast Scheduled For Wednesday, August 3, 2016

Bearish Bets: Biotech, Energy and Other Stocks that Look Good to Short

NBIX, ZPIN, VLP, NWLI and INFO were all recently downgraded by TheStreet's Quant Ratings.

Biogen Should Either a Buyer or a Seller Be

Biogen Should Either a Buyer or a Seller Be

The company sans CEO Scangos needs to do some type of deal in the coming months.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ESNT, HBHC, HMY, IILG, MYCC, NEWM, PRTY, TOT, VTTI Downgrades: NBIX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Short Interest In Neurocrine Biosciences Decreases By 30%

Short Interest In Neurocrine Biosciences Decreases By 30%

The most recent short interest data has been released for the 06/30/2016 settlement date, which shows a 1,864,374 share decrease in total short interest for Neurocrine Biosciences, Inc. , to 4,324,184, a decrease of 30.13% since 06/15/2016.

Neurocrine Biosciences To Present At The Jefferies 2016 Healthcare Conference

Neurocrine Biosciences To Present At The Jefferies 2016 Healthcare Conference

Live Audio Webcast will be on June 8, 2016

Neurocrine Biosciences (NBIX) Strong On High Relative Volume Today

Neurocrine Biosciences (NBIX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a strong on high relative volume candidate

Insider Trading Alert - NBIX, FRGI And LBAI Traded By Insiders

Insider Trading Alert - NBIX, FRGI And LBAI Traded By Insiders

Stocks with insider trader activity include NBIX, FRGI and LBAI

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

The biotechnology company, which makes alcoholism drug Horizant, was acquired by privately held Arbor Pharmaceuticals for $467 million in cash, a price lower than at least one analyst expected.

Strong On High Volume: Neurocrine Biosciences (NBIX)

Strong On High Volume: Neurocrine Biosciences (NBIX)

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a strong on high relative volume candidate

Short Interest Moves 11% Higher For NBIX

Short Interest Moves 11% Higher For NBIX

The most recent short interest data has been released for the 04/29/2016 settlement date, which shows a 692,785 share increase in total short interest for Neurocrine Biosciences, Inc. , to 6,943,712, an increase of 11.08% since 04/15/2016.

Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference

Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference

Live Audio Webcast will be on May 12, 2016

Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2016 Results

Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2016 Results

Conference Call and Webcast Scheduled For Thursday, May 5, 2016

Neurocrine Biosciences To Present At The Deutsche Bank 41st Annual Health Care Conference

Neurocrine Biosciences To Present At The Deutsche Bank 41st Annual Health Care Conference

Live Audio Webcast will be on May 4, 2016

'Mad Money' Lightning Round: I'm Taking Starbucks Over Bojangles

'Mad Money' Lightning Round: I'm Taking Starbucks Over Bojangles

Cramer prefers Southwest over JetBlue and is waiting on Boeing.

Jim Cramer's 'Mad Money' Recap: Uncle Sam, Back Off Business!

Jim Cramer's 'Mad Money' Recap: Uncle Sam, Back Off Business!

Cramer says the political rhetoric against Big Business is heading down a dangerous path.

Neurocrine Biosciences (NBIX) Stock Gets ‘Outperform’ Rating at BMO Capital

Neurocrine Biosciences (NBIX) Stock Gets ‘Outperform’ Rating at BMO Capital

Neurocrine Biosciences (NBIX) stock was started with an ‘outperform’ rating and $57 price target at BMO Capital Markets.

Neurocrine Biosciences To Present At The Barclays Global Healthcare Conference

Neurocrine Biosciences To Present At The Barclays Global Healthcare Conference

Live Audio Webcast will be on March 15, 2016

Neurocrine Biosciences To Present At The Cowen And Company 36th Annual Health Care Conference

Neurocrine Biosciences To Present At The Cowen And Company 36th Annual Health Care Conference

Live Audio Webcast will be on March 9, 2016

Neurocrine Biosciences Announces Conference Call And Webcast To Report Fourth Quarter And Year-End 2015 Results

Neurocrine Biosciences Announces Conference Call And Webcast To Report Fourth Quarter And Year-End 2015 Results

Conference Call and Webcast Scheduled For Thursday, February 11, 2016

Neurocrine Biosciences To Present At The Leerink Partners 5th Annual Global Healthcare Conference

Neurocrine Biosciences To Present At The Leerink Partners 5th Annual Global Healthcare Conference

Live Audio Webcast will be on February 10, 2016

Neurocrine Announces Initiation Of Phase II Clinical Study Of VMAT2 Inhibitor Valbenazine In Children And Adolescents With Tourette Syndrome

Neurocrine Announces Initiation Of Phase II Clinical Study Of VMAT2 Inhibitor Valbenazine In Children And Adolescents With Tourette Syndrome

Six-Week T-Force GREEN Study to Assess the Safety, Tolerability and Efficacy of Valbenazine in 90 Pediatric Subjects

AbbVie Initiates Enrollment In Phase 3 Clinical Program For Elagolix In Patients With Uterine Fibroids

AbbVie Initiates Enrollment In Phase 3 Clinical Program For Elagolix In Patients With Uterine Fibroids

- The Elagolix Phase 3 uterine fibroid clinical development program includes two replicate, pivotal, six-month efficacy and safety studies followed by a six-month safety and efficacy extension study.

Neurocrine Biosciences To Present At The 34th Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences To Present At The 34th Annual J.P. Morgan Healthcare Conference

Live Audio Webcast will be on January 11, 2016

Neurocrine Announces Successful Completion Of Phase Ib T-Force Study Of VMAT2 Inhibitor NBI-98854 In Adolescents And Children With Tourette Syndrome

Neurocrine Announces Successful Completion Of Phase Ib T-Force Study Of VMAT2 Inhibitor NBI-98854 In Adolescents And Children With Tourette Syndrome

Once-Daily Valbenazine was Safe and Well Tolerated with a 31% Reduction from Baseline in Tourette Symptoms after Two Weeks of Treatment